Genetic Multigene Panel Analysis in Women Diagnosed with Invasive Lobular Carcinoma
By
Giovanni Corso
Elena Marino
Francesca Fava
Fabrizio Natali
Paolo Peterlongo
Matteo Dal Molin
Irene Feroce
Cristina Zanzottera
Giulia Massari
Susanna Di Silvestre
Micol Moscatiello
Andrea Franceschini
Vincenzo Bagnardi
Giuseppe Curigliano
Bernardo Bonanni
Paolo Veronesi
Francesco Bertolini
July 8, 2026
Clinical Scorecard: Genetic Multigene Panel Analysis in Women Diagnosed with Invasive Lobular Carcinoma
At a Glance
Category Detail
Condition Invasive Lobular Carcinoma Key Mechanisms Germline pathogenic variants in genes such as CDH1 and BRCA2 are associated with increased risk. Target Population Women diagnosed with primary invasive lobular carcinoma. Care Setting European Institute of Oncology
Key Highlights
ILC accounts for 10% to 15% of all breast cancer cases. Established risk factors include hormone replacement therapy and family history of breast cancer. Germline PVs in CDH1 and BRCA2 confer high risk for ILC. The study evaluates outcomes of germline PVs in a large cohort of ILC patients. Polygenic risk scores may serve as prognostic markers in ILC. Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of primary ILC through histopathologic evaluation. Management
Consider genetic counseling and multigene panel testing for women diagnosed with ILC. Monitoring & Follow-up
Systematic recording of clinical, histopathologic, personal, and family history data. Risks
Monitor for the presence of germline pathogenic variants associated with breast cancer risk. Patient & Prescribing Data
Women diagnosed with invasive lobular carcinoma, particularly those diagnosed before age 40.
Emerging targeted treatments may be relevant for patients with BRCA-mutated tumors.
Clinical Best Practices
Utilize genetic testing to inform tailored surveillance strategies. Implement psychological counseling for patients undergoing genetic testing. Related Resources & Content
